Arginine (Di)methylated Human Leukocyte Antigen Class I Peptides Are Favorably Presented by HLA-B*07.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Mommen, Geert P M
Meiring, Hugo D
van Gaans-van den Brink, Jacqueline A M
Scheltema, Richard A
van Els, Cécile A C M
Heck, Albert J R
MetadataShow full item record
TitleArginine (Di)methylated Human Leukocyte Antigen Class I Peptides Are Favorably Presented by HLA-B*07.
Published inJ Proteome Res 2017; 16(1):34-44
PubliekssamenvattingAlterations in protein post-translational modification (PTM) are recognized hallmarks of diseases. These modifications potentially provide a unique source of disease-related human leukocyte antigen (HLA) class I-presented peptides that can elicit specific immune responses. While phosphorylated HLA peptides have already received attention, arginine methylated HLA class I peptide presentation has not been characterized in detail. In a human B-cell line we detected 149 HLA class I peptides harboring mono- and/or dimethylated arginine residues by mass spectrometry. A striking preference was observed in the presentation of arginine (di)methylated peptides for HLA-B*07 molecules, likely because the binding motifs of this allele resemble consensus sequences recognized by arginine methyl-transferases. Moreover, HLA-B*07-bound peptides preferentially harbored dimethylated groups at the P3 position, thus consecutively to the proline anchor residue. Such a proline-arginine sequence has been associated with the arginine methyl-transferases CARM1 and PRMT5. Making use of the specific neutral losses in fragmentation spectra, we found most of the peptides to be asymmetrically dimethylated, most likely by CARM1. These data expand our knowledge of the processing and presentation of arginine (di)methylated HLA class I peptides and demonstrate that these types of modified peptides can be presented for recognition by T-cells. HLA class I peptides with mono- and dimethylated arginine residues may therefore offer a novel target for immunotherapy.
- A proteomic analysis of arginine-methylated protein complexes.
- Authors: Boisvert FM, Côté J, Boulanger MC, Richard S
- Issue date: 2003 Dec
- TDRD3 is an effector molecule for arginine-methylated histone marks.
- Authors: Yang Y, Lu Y, Espejo A, Wu J, Xu W, Liang S, Bedford MT
- Issue date: 2010 Dec 22
- Synthesis and biological evaluation of two chemically modified peptide epitopes for the class I MHC protein HLA-B*2705.
- Authors: Jones MA, Hislop AD, Snaith JS
- Issue date: 2006 Oct 21
- Tumor necrosis factor (TNF)-α induction of CXCL10 in endothelial cells requires protein arginine methyltransferase 5 (PRMT5)-mediated nuclear factor (NF)-κB p65 methylation.
- Authors: Harris DP, Bandyopadhyay S, Maxwell TJ, Willard B, DiCorleto PE
- Issue date: 2014 May 30
- Nonclassical HLA-G molecules are classical peptide presenters.
- Authors: Diehl M, Münz C, Keilholz W, Stevanović S, Holmes N, Loke YW, Rammensee HG
- Issue date: 1996 Mar 1